No compensation in CD44 stem cell marker following BCL-2 suppression by antisense oligonucleotides

In Vivo

Volumn 27, Issue 2, 2013, Pages 251-256

  Rubenstein, Marvin ^a,b,c   Hollowell, Courtney M P ^b   Guinan, Patrick ^a,b,c,d  

^a Hektoen Institute for Medical Research   (United States)

^b Jr Hospital of Cook County   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antisense; BCL 2; CD44; Prostate cancer; Therapy

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; HERMES ANTIGEN; PROTEIN BCL 2;

ADVANCED CANCER; ARTICLE; CANCER CELL CULTURE; DRUG MECHANISM; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; STEM CELL;

EID: 84876916381     PISSN: 0258851X     EISSN: 17917549     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Rubenstein M, Hollowell CMP and Guinan P: Inhibition of BCL-2 by antisense oligonucleotides is followed by a compensatory suppression of caspase-3 in LNCaP cells. Eur J Clin Med Oncol 3: 1-6, 2011.
2. Mu Z, Hachem P and Pollack A: Antisense BCL-2 sensitizes prostate cancer cells to radiation. Prostate 65: 331-340, 2005.
3. Yip KW, Mocanu JD, Au PY, Sleep GT, Busson D, Yeh P, Gilbert WC, O'Sullivan R, Gullane B, Bastianutto C and Liu FF: Combination BCL-2 antisense and radiation therapy for nasopharyngeal cancer. Clin Cancer Res 11: 8131-8144, 2005.
4. Yamanaka K, Miyake H, Zangemeister-wittke U, Jansen B and Gleave M: Novel bispecific antisense oligonucleotides inhibiting both BCL-2 and BCL-xL expression induce apoptosis and enhance chemosensitivity in human androgen-independent prostate cancer cells. Proc AACR 45: (online) abstract #2930, 2004.
5. Rubenstein M, Hollowell CMP and Guinan P: In LNCaP cells enhanced expression of the androgen receptor compensates for BCL-2 suppression by antisense oligonucleotides. Ther Adv Urology 3: 73-79, 2011.
6. Rubenstein M, Hollowell CMP and Guinan P: In LNCaP cells enhanced expression of both androgen receptor and co-stimulatory protein p300 compensate for antisense oligonucleotide suppression of bcl-2. Ther Adv Urology 3: 243-250, 2011.
7. Rubenstein, M., Hollowell, CMP and Guinan, P: Increased expression of the androgen receptor with p300 and IL-6 coactivators compensate for oligonucleotide suppression of BCL-2. No increased CREBBP or IL-4 expression. Published online SAGE Journals November 8, 2012 DOI-10.1177/1756287212466281. (Manuscript in Press: Therapeutic Advances in Urology).
8. Rubenstein M, Hollowell CMP and Guinan P: Multiple pathways compensate for antisense suppression of BCL-2 in LNCaP cells contributing to tumor resistance. J Physiobiochem Metab 1: 2, 2012
9. Rubenstein M, Hollowell CMP and Guinan P: Increased prostate specific membrane antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFR. Med Oncol 27: 1212-1218, 2010.
10. Rubenstein M, Hollowell CMP and Guinan P: Bispecific oligonucleotides may induce interferon in LNCaP cells enhancing surface antigen expression: Effect of intra-strand base-pair complementarity. In Vivo 25: 61-67, 2011.
11. Rubenstein M and Guinan P: Bispecific antisense oligonucleotides have activity comparable to monospecifics in inhibiting expression of BCL-2 in LNCaP cells. In Vivo 24: 489-93, 2012.
12. Oncogenex website: www.Oncogenex.ca
13. Genta website: ww.genta.com/Products-and-Pipeline/Genasense/ Genasense.html
14. Rubenstein M, Hollowell CMP and Guinan P: Bax expression remains unchanged following antisense treatment directed against BCL-2. Med Oncol 28: 852-858, 2011.
15. Pandini G, Mineo R, Frasca F, Roberts CT Jr., Marcelli M, Vigneri R and Belfiore A: Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res 65: 1849-1857, 2005.
16. Heemers HV, Sebo TJ, Debes JD, Regan KM, Raclaw KA, Murphy LM, Hobisch A, Culig Z and Tindall DJ: Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res 67: 3422-3430, 2007.
17. Debes JD, Comuzzi B, Schmidt LJ, Dehm SM, Culig Z and Tindall DJ: P300 regulates androgen receptor-independent expression of prostate specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res 65: 5965- 5973, 2005.
18. Klocker H, Eder IE, Comuzzi B, Bartsch G and Culig Z: Androgen receptor function in prostate cancer progression. In: Prostate Cancer. Chung LWK, Isaacs WB and Simons JW (eds.). Totowa, NJ, Humana Press, p. 94, 2007.
19. Rubenstein M, Hollowell CMP and Guinan P: Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFR. Med Oncol 29: 835-841, 2012.
20. Rubenstein M, Hollowell CMP and Guinan P: No compensation in VEGF expression follows antisense suppression of BCL-2 activity. In Vivo 26: 937-940, 2012.
21. American Cancer Society, Cancer Facts & Figures 2012. Atlanta: American Cancer Society, 2012.